Domain Therapeutics is a biopharmaceutical company. It uses transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer.
|Employees (est.) (Oct 2020)||61||(-1%)|
Domain Therapeutics total Funding
Domain Therapeutics latest funding size
Time since last funding
|a year ago|
Domain Therapeutics investors
|Bpifrance, Seventure Partners, Idinvest Partners, Sofinnova Partners, Auriga Partners, Groupe Siparex, The Michael J. Fox Foundation, Andera Partners, Alsace création, Airfi aero, SODIV ALSACE|
Domain Therapeutics has 201 Twitter Followers. The number of followers has increased 2.4% month over month and increased 9.3% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Domain Therapeutics founded?
Domain Therapeutics was founded in 2001.
Who are Domain Therapeutics key executives?
Domain Therapeutics's key executives are Youssef L. Bennani, Pascal Neuville and Sébastien Groyer.
How many employees does Domain Therapeutics have?
Domain Therapeutics has 61 employees.
Who are Domain Therapeutics competitors?
Competitors of Domain Therapeutics include Calypso Biotech, Lumen Bioscience and Veritas In Silico.
Where is Domain Therapeutics headquarters?
Domain Therapeutics headquarters is located at 1 Bd Sébastien Brant, Illkirch-Graffenstaden.
Where are Domain Therapeutics offices?
Domain Therapeutics has offices in Illkirch-Graffenstaden and Montréal.
How many offices does Domain Therapeutics have?
Domain Therapeutics has 2 offices.
Receive alerts for 300+ data fields across thousands of companies